Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Reuters

2025/07/15

Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Ascletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551395411"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551395411\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551395411?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551395411","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-15 06:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6Kd4cT:1","article_id":"2551395411","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551395411","pubTimestamp":1752533493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 , involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47  or a placebo, along with four doses of semaglutide . The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","01672":"歌礼制药-B","BK1161":"生物科技","BK1515":"抗疫概念"},"translate_title":"歌礼制药联合ASC47和索马鲁肽治疗肥胖美国临床试验完成给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    \n\nAscletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}